Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib As First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Overview

Journal Front Pharmacol

Date 2022 Feb 28

PMID 35222020

Authors

Ye Peng

Xiaohui Zeng

Liubao Peng

Qiao Liu

Lidan Yi

Xia Luo

Sini Li

Liting Wang

Shuxia Qin

Xiaomin Wan

Chongqing Tan

Affiliations

Soon will be listed here.

Abstract

: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar as a first-line treatment for unresectable hepatocellular carcinoma from the Chinese perspective of healthcare system. : A Markov model with three mutual health states was constructed to evaluate the economic outcome of sintilimab plus bevacizumab biosimilar. The model cycle was 21 days, and the simulation time horizon was a lifetime. The output parameters of the model were the total cost, life-year (LY), quality-adjusted LY (QALY), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses were conducted to assess the robustness of the results. : The base-case results found that sintilimab plus bevacizumab biosimilar provided an improvement of 1.27 QALYs and 1.84 LYs compared with sorafenib, and the ICER was $23,352/QALY. The hazard ratio for OS had the greatest influence on the ICER. The probability of sintilimab plus bevacizumab biosimilar was 85% at willingness-to-pay thresholds of $30,552/QALY. : The findings of this analysis suggested that sintilimab plus bevacizumab biosimilar was a cost-effective first-line therapy for patients with unresectable hepatocellular carcinoma.

Citing Articles

Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer.

Wei X, Cao W, Wang S, Zhang Y, Gao Z, Wang S Int J Nanomedicine. 2025; 20:2623-2643.

PMID: 40061885 PMC: 11887507. DOI: 10.2147/IJN.S509409.

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma.

Zou H, Lai Y, Chen X, Ung C, Hu H Therap Adv Gastroenterol. 2025; 18:17562848241310314.

PMID: 39758963 PMC: 11694292. DOI: 10.1177/17562848241310314.

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China.

Zhao Z, Jiang X, Wen S, Hao Y Front Oncol. 2024; 14:1491404.

PMID: 39711961 PMC: 11659146. DOI: 10.3389/fonc.2024.1491404.

Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.

Cai H, Lin J, Zhu H, Zheng Z BMJ Open. 2024; 14(12):e079603.

PMID: 39663164 PMC: 11647293. DOI: 10.1136/bmjopen-2023-079603.

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer.

You M, Luo L, Lu T, Chen S, He Y Front Immunol. 2024; 15:1477146.

PMID: 39654891 PMC: 11625741. DOI: 10.3389/fimmu.2024.1477146.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Mahipal A, Tella S, Kommalapati A, Lim A, Kim R . Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. Cancers (Basel). 2019; 11(8). PMC: 6721326. DOI: 10.3390/cancers11081078. View

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

Chiang C, Chan S, Lee S, Wong I, Choi H . Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Netw Open. 2021; 4(1):e2033761. PMC: 7816108. DOI: 10.1001/jamanetworkopen.2020.33761. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Sanders G, Neumann P, Basu A, Brock D, Feeny D, Krahn M . Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016; 316(10):1093-103. DOI: 10.1001/jama.2016.12195. View

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

Kohn C, Zeichner S, Chen Q, Montero A, Goldstein D, Flowers C . Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017; 35(11):1194-1202. PMC: 5791832. DOI: 10.1200/JCO.2016.69.6336. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

10.

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

11.

Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y . Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2020; 8(6):989-999. PMC: 6976344. DOI: 10.21037/tlcr.2019.12.23. View

12.

Gao S, Li N, Gao S, Xue Q, Ying J, Wang S . Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020; 15(5):816-826. DOI: 10.1016/j.jtho.2020.01.017. View

13.

Li M, Lin S, Wilson L, Huang P, Wang H, Lai S . Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion. Front Oncol. 2021; 11:562135. PMC: 7985441. DOI: 10.3389/fonc.2021.562135. View

14.

Su D, Wu B, Shi L . Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Netw Open. 2021; 4(2):e210037. PMC: 7905498. DOI: 10.1001/jamanetworkopen.2021.0037. View

15.

Hou Y, Wu B . Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Commun (Lond). 2020; 40(12):743-745. PMC: 7743015. DOI: 10.1002/cac2.12110. View

16.

Chiang C, Chan S, Lee S, Choi H . First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers (Basel). 2021; 13(5). PMC: 7956424. DOI: 10.3390/cancers13050931. View

17.

Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q . Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states. Liver Int. 2021; 41(5):1097-1104. DOI: 10.1111/liv.14795. View

18.

Neumann P, Cohen J, Weinstein M . Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796-7. DOI: 10.1056/NEJMp1405158. View

19.

Murray C, Evans D, Acharya A, Baltussen R . Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000; 9(3):235-51. DOI: 10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o. View

20.

Saung M, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M . FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist. 2021; 26(9):797-806. PMC: 8417871. DOI: 10.1002/onco.13819. View